Prospective Efficacy of Osimertinib in Circulating Tumour DNA (ctDNA) T790M-Mutant NSCLC Patients [P2.13-24]

Remon, J.; Jovelet, C.; Lacroix, L.; Planchard, D.; Mezquita, L.; Howarth, K.; Green, E.; Plagnol, V.; Morris, C.; Rosenfeld, N.; Caramella, C.; Lepéchoux, C.; Aboubakar Nana, Frank; Botticella, A.; Adam, J.; Ferrara, R.; Gazzah, A.; Ngocamus, M.; Soria, J.; Besse, B.

doi:10.1016/j.jtho.2018.08.1419

Prospective Efficacy of Osimertinib in Circulating Tumour DNA (ctDNA) T790M-Mutant NSCLC Patients [P2.13-24]

Remon, J.

;

Jovelet, C.

;

Lacroix, L.

;

Planchard, D.

;

Besse, B.

;et.al.

(2018) IASLC 19th World Conference on Lung Cancer — Location: (Canada) Toronto (23.September.2018)

Files

2018_Remon_J_Thorac_Oncol_P213-24.pdf

Open Access
Adobe PDF
476.09 KB

Download

Details

Authors

Remon, J.
Author
Jovelet, C.
Author
Lacroix, L.
Author
Planchard, D.
Author
Aboubakar Nana, FrankUCLouvain
Author
Besse, B.
Author

Abstract

BACKGROUND : Liquid biopsy circulating tumor DNA (ctDNA) analysis in advanced EGFR-mutant NSCLC patients is an approved tool for molecular profiling and disease surveillance when tissue is not available. Long-term efficacy of osimertinib in patients with the T790M resistance mutation positive detected only by ctDNA (without tissue information) has not been fully validated. [...]

Affiliations

Citations

APA
Chicago
FWB

Remon, J., Jovelet, C., Lacroix, L., Planchard, D., Mezquita, L., Howarth, K., Green, E., Plagnol, V., Morris, C., Rosenfeld, N., Caramella, C., Lepéchoux, C., Aboubakar Nana, F., Botticella, A., Adam, J., Ferrara, R., Gazzah, A., Ngocamus, M., Soria, J., & Besse, B. (2018). Prospective Efficacy of Osimertinib in Circulating Tumour DNA (ctDNA) T790M-Mutant NSCLC Patients [P2.13-24]. Journal of Thoracic Oncology, 13(10), S807-S808. https://doi.org/10.1016/j.jtho.2018.08.1419 (Original work published 2018)